Cedarburg Hauser Pharmaceuticals
Date | Investors | Amount | Round |
---|---|---|---|
$7.0m | Series A | ||
$41.0m Valuation: $41.0m | Acquisition | ||
Total Funding | CAD9.5m |
Related Content
Recent News about Cedarburg Hauser Pharmaceuticals
EditCedarburg Hauser Pharmaceuticals, a subsidiary of Albany Molecular Research Inc. (AMRI), specializes in providing comprehensive drug development and manufacturing services to pharmaceutical companies. Operating in the pharmaceutical and biotechnology sectors, the company offers a range of services including API (Active Pharmaceutical Ingredient) development, drug product manufacturing, and analytical testing. Cedarburg Hauser Pharmaceuticals serves clients ranging from small biotech firms to large pharmaceutical companies, helping them navigate the complex journey from drug discovery to market. The business model is service-based, generating revenue through contracts for drug development, manufacturing, and testing services. By leveraging its integrated approach and industry-leading expertise, Cedarburg Hauser Pharmaceuticals ensures high-quality and efficient drug development processes for its clients.
Keywords: drug development, API manufacturing, pharmaceutical services, biotechnology, analytical testing, drug discovery, contract manufacturing, pharmaceutical clients, integrated services, high-quality production.